SAN JOSE, Calif., April 30, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference, to be held on May 20, 2025, at Nasdaq World Headquarters in New York City.Mike Catelani, President and CFO of Anixa, will deliver a presentation and will be available for one-on-one meetings during the conference.Details ...

Anixa Biosciences (ANIX) shares gained 13% on Wednesday following the announcement that the U.S. Patent and Trademark Office has issued a new patent for its groundbreaking breast cancer vaccine technology.In collaboration with Cleveland Clinic, the company is developing a vaccine to treat and prevent breast cancer in an early-stage study.The new patent expands the scope of immunogenic compositions used in Anixa Biosciences’ breast cancer vaccine. It encompasses methods for immunizing patients against breast ...

Patent Broadens Immunogenic Compositions for Preventive Vaccine Approach About Anixa Biosciences, Inc. Contact: SAN JOSE, Calif., April 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new patent related to the Company's innovative breast cancer vaccine technology. The patent alon ...

Mike Catelani, President and CFO of Anixa, will deliver a presentation and be available for one-on-one meetings during the conference. Details of the presentation are as follows: Event: Jones Healthcare and Technology Innovation Conference Date: April 9, 2025 Time: 4:30 PM PT Location: The Venetian Resort Webcast: https://wsw.com/webcast/jones2/anix/1888272 SAN JOSE, Calif., April 1, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on th ...

VERDI's personalized vaccines have demonstrated safety and efficacy in cancer patientsSAN JOSE, Calif., March 25, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a letter of intent with VERDI Solutions, GmbH to develop personalized and off-the-shelf peptide vaccines for cancer patients.VERDI Solutions, headquartered in Vienna, Austria, is pioneering pers ...

SAN JOSE, Calif., March 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent application covering its ovarian cancer vaccine technology. The patent includes broad claims related to methods of eliciting an immune response targeting Anti-Mullerian Hormone Receptor, Type II ( ...

SAN JOSE, Calif., March 17, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and Chief Executive Officer, Dr. Amit Kumar, will be presenting at the 2025 Cancer Advocacy Group of Louisiana ("CAGLA") NeauxCancer Conference taking place on March 27-29, 2025 at the The Roosevelt Hotel in New Orleans.Dr. Kumar's presentation will provide an overview of Anixa's pionee ...

Revenue Performance - Revenue for the three months ended January 31, 2025, was $0, consistent with the same period in 2024[81]. - The company does not expect to begin generating revenue from its current therapy or vaccine programs in the near term[82]. Expenses - Research and development expenses increased by approximately $203,000 to approximately $1,552,000 for the three months ended January 31, 2025, compared to approximately $1,349,000 in the same period in 2024[84]. - General and administrative expenses decreased by approximately $426,000 to approximately $1,834,000 for the three months ended January 31, 2025, from approximately $2,260,000 in the same period in 2024[86]. - Interest income decreased by approximately $146,000 to approximately $173,000 for the three months ended January 31, 2025, from approximately $319,000 in the same period in 2024[87]. Assets and Cash Flow - Total current assets decreased by approximately $2,676,000 to approximately $18,686,000 as of January 31, 2025, compared to approximately $21,362,000 at October 31, 2024[90]. - Cash used in operating activities was approximately $2,904,000 for the three months ended January 31, 2025[91]. - Cash provided by investing activities was approximately $2,703,000, resulting from the maturities of short-term investments of approximately $15,700,000[91]. - The company has approximately $97 million of common stock available for sale under its at-the-market equity program as of January 31, 2025[90]. Net Loss - The net loss attributable to noncontrolling interest decreased by approximately $6,000 to approximately $29,000 for the three months ended January 31, 2025[88].

Company Overview - Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on cancer treatment and prevention [3] - The company has a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center, utilizing chimeric endocrine receptor-T cell (CER-T) technology [3] - Anixa's vaccine portfolio includes vaccines for breast and ovarian cancer, developed in collaboration with Cleveland Clinic, as well as additional vaccines targeting high incidence malignancies such as lung, colon, and prostate cancers [3] - The company partners with renowned research institutions to explore emerging technologies for further development and commercialization [3] Upcoming Events - Anixa will host its 2025 Annual Meeting of Stockholders on March 20, 2025, at 10:00 a.m. Pacific Time in a virtual format [1] - Following the formal business and voting portion, Anixa's Chairman and CEO, Dr. Amit Kumar, will deliver an investor presentation and corporate update, followed by a Q&A session [2] - Interested parties can access the meeting online at www.virtualshareholdermeeting.com/ANIX2025 [2]

Core Viewpoint - Anixa Biosciences, Inc. is actively participating in the Alliance for Cancer Gene Therapy Summit 2025, highlighting its advancements in cancer treatment, particularly in cell and gene therapy for gynecologic and breast cancers [1][2][3] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [5] - The company is also developing vaccines in partnership with Cleveland Clinic to treat and prevent breast and ovarian cancers, as well as other cancer vaccines targeting high incidence malignancies such as lung, colon, and prostate cancers [5] - Anixa employs a unique business model that involves partnering with renowned research institutions throughout all stages of development, allowing for the exploration of emerging technologies in complementary fields [5] Event Participation - Dr. Pam Garzone, Chief Development Officer of Anixa, will be a panelist at the ACGT Summit, discussing advancements in cell and gene therapy, including Anixa's CAR-T therapy for ovarian cancer [2][3] - The panel discussion is scheduled for March 19, 2025, from 11:15 AM to 12:15 PM ET, at the Alexandria Center for Life Science in New York City [1][2]